Skip to main content

Table 2 Summary of the pooled OR

From: Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer

  Studies Overall OR (95 % CI) I2; p P value Cases Controls p (Egger’s test)
Cancer vs. Normal 10 6.18 (4.02–9.51) 0.0 %; 0.679 <0.001 706 429 0.197
Subgroup        
Sample type        
Blood 2 18.71 (2.41–145.20) 39.6 %; 0.198 0.005 55 82  
Tissue 9 5.74 (3.68–8.95) 0.0 %; 0.818 < 0.001 651 347  
Race        
Caucasians 5 5.39 (3.25–8.94) 0.0 %; 0.981 < 0.001 294 155  
Asians 5 8.34 (3.63–19.13) 40.1 %; 0.154 < 0.001 567 274  
Cancer vs. Benign 7 3.26 (1.65–6.44) 0.0 %; 0.938 0.001 431 109 0.172
Cancer vs. LMP 5 1.30 (0.67–2.51) 0.0 %; 0.663 0.436 319 75 0.199
Clinicopathological features      Cancer patients  
      Low-grade High-grade  
Tumor grade 4 0.46 (0.13–1.65) 68.5 %; 0.013 0.233 116 148 0.488
      StageI-II Stage III-IV  
Tumor stage 5 0.76 (0.31–1.88) 61.0 %; 0.025 0.558 188 278 0.449
      Serous carcinoma Non-serous carcinoma  
Tumor histology 7 0.56 (0.35–0.91) 0.0 %; 0.584 0.02 193 217 0.238
  1. LMP low malignant potential tumor, OR odds ratio, 95 % CI 95 % confidence interval